Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade

Basit Öğe Kaydı
dc.contributor.authorKocyigit, Duygu
dc.contributor.authorGurses, Kadri Murat
dc.contributor.authorYalcin, Muhammed Ulvi
dc.contributor.authorTokgozoglu, Lale
dc.date.accessioned2020-03-26T19:33:54Z
dc.date.available2020-03-26T19:33:54Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractType 2 diabetic patients are known to have a tendency to develop cardiovascular (CV) disease (CVD), and related unfavourable outcomes such as heart failure, myocardial infarction (MI), cerebrovascular events (e.g. stroke), and related mortality. Long-term clinical trials have revealed contradictory findings regarding the relationship between glycemic control and CV benefits due to variations in the key characteristics of the study population. During the last decade, number of pharmacological agents used for glucose-lowering in the treatment of type 2 diabetes mellitus (T2DM) has increased owing to the introduction of dipeptidyl peptidase-IV (DPP-IV) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose co-transporter 2 (SGLT-2) inhibitors. This review aims to focus on the mechanisms of action of these drugs in the cardiovascular system and the trials evaluating their impact on CVD. Furthermore, trials in the last decade evaluating the impact of traditional glucose-lowering drugs on CVD are included. For this purpose, we searched PubMed for articles in English using the search terms "type 2 diabetes mellitus, glucose-lowering drugs, antidiabetic medications, cardiovascular, cardiovascular disease, cardiovascular system" between inception to September 2016. We also searched separately for each medication in addition to the keyword "cardiovascular disease" on PubMed. To identify further articles, we hand searched related citations in review articles and commentaries.en_US
dc.identifier.doi10.2174/1871530317666170424101846en_US
dc.identifier.endpage31en_US
dc.identifier.issn1871-5303en_US
dc.identifier.issn2212-3873en_US
dc.identifier.issue1en_US
dc.identifier.pmid28440199en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage19en_US
dc.identifier.urihttps://dx.doi.org/10.2174/1871530317666170424101846
dc.identifier.urihttps://hdl.handle.net/20.500.12395/34805
dc.identifier.volume17en_US
dc.identifier.wosWOS:000404993200004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBENTHAM SCIENCE PUBL LTDen_US
dc.relation.ispartofENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETSen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjecthyperglycemiaen_US
dc.subjectglucose-lowering drugsen_US
dc.subjectcardiovascularen_US
dc.subjectdipeptidyl peptidase-IV inhibitorsen_US
dc.subjectglucagon-like peptide-1 receptor agonistsen_US
dc.subjectsodium-glucose co-transporter 2 inhibitorsen_US
dc.titleAnti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decadeen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu